Two major Covid-19 vaccines have started phase 3 clinical trials and are expected to complete by the end of 2020. If the results prove to be significant and safe and receive fast track FDA approval, there should be vaccines available in the first half of 2021.
The University of Oxford trial is recruiting 50,000 volunteers and the Moderna trial is enrolling 30,000 subjects. Both companies are proceeding with parallel plans to manufacture the vaccine so that if approved there will be minimal delay before the vaccines are available.
There is also recent news of a Covid-19 vaccine developed by Russia. Under revised Russian law, the vaccine has been released before a phase 3 clinical trial has been completed. This has received widespread condemnation for being unsafe.
https://www.cnn.com/2020/08/11/europe/russia-coronavirus-vaccine-putin-intl/index.html
In fact what the Russians are doing may not be that different. The Moderna and Oxford trials are trying a drug on an experimental basis on 80,000 people, before any phase 3 trial results are known. If the Russians review the results of their vaccine after it has been given to 50,000 patients, they may determine that the vaccine is not safe and/or not effective and may withdraw it. This is not very different from the Oxford trial.
What really irks the U.S. and U.K. is that Russia, like Oxford and Moderna is proceeding with manufacturing the vaccine, but has jumped ahead of them by making deals with 20 countries to sell them more than one billion doses of their vaccine.
So what is the impact of having a Covid-19 vaccine in early 2021?
We ran a model simulation for Canada. If 100,000 people per day can be vaccinated starting in April 2021, then by the end of Oct 2021, daily coronavirus cases decline to 0. At that point population immunity is 60%. This would be “herd” immunity.
This result is generic and can be applied to any country. If a country can vaccinate 0.25% of its population per day, it can achieve herd immunity in 8 months.